Estimated market cap $449.19MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Nov 10, 2026, last close Nov 13, 2026.106.69M shares, shares as of Nov 10, 2026CIK 1553643The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
6 buys · 0 sells
$1.83M bought, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
IPO prospectus
Relmada Therapeutics, Inc.’s initial public offering: where it stands and what the registration statement says.
Loading…
Latest 10-Q
What changed in Relmada Therapeutics, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Relmada Therapeutics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
77
43.5% of shares · 32 added
IPO prospectus
Updated
Relmada Therapeutics, Inc.’s initial public offering: where it stands and what the registration statement says.
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of the prospectus. Written by AI from the parts of the prospectus listed in the filing, and checked against its text. This is information, not investment advice.
What changed in Relmada Therapeutics, Inc.'s latest quarterly report, compared with the one before.
Filed Nov 12, 2026 · Quarter ended Sep 30, 2026
AI No AI summary for this 10-Q: the draft did not pass our accuracy checks.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Sep 10, 2026. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
77 funds report RLMD. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 94% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 100.23M reported shares by 106.67M shares, from the company’s SEC filing as of Aug 4, 2026.
126 funds hold the stock.
Q3 2026: 44% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202516%
Q3 202511%
Q4 202571%
Q1 202681%
Q2 202694%
Q3 2026 (so far)44%
Q3 2026. 12 new, 32 added to, 18 trimmed, 61 exited since Q2 2026.
Download CSVEvery fund that holds RLMD, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Relmada Therapeutics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q4 2019
45
—
6.89M
$268.9M
Q1 2020
43
-2
9.36M
$319.2M
Q2 2020
75
+32
10.51M
$469.3M
Q3 2020
72
-3
10.44M
$392.9M
Q4 2020
80
+8
9.32M
$299.1M
Q1 2021
82
+2
9.54M
$335.7M
Q2 2021
85
+3
9.94M
$318.3M
Q3 2021
87
+2
10.03M
$262.8M
Q4 2021
97
+10
20.76M
$467.7M
Q1 2022
112
+15
23.08M
$623.1M
Q2 2022
113
+1
24.68M
$478.5M
Q3 2022
134
+21
25.78M
$953.9M
Q4 2022
110
-24
19.14M
$66.8M
Q1 2023
90
-20
17.86M
$40.4M
Q2 2023
95
+5
16.11M
$39.7M
Q3 2023
88
-7
15.00M
$45.0M
Q4 2023
83
-5
13.73M
$56.8M
Q1 2024
93
+10
14.73M
$68.5M
Q2 2024
79
-14
13.91M
$41.7M
Q3 2024
69
-10
12.69M
$41.3M
Q4 2024
48
-21
8.40M
$4.4M
Q1 2025
44
-4
6.22M
$1.7M
Q2 2025
50
+6
5.30M
$3.2M
Q3 2025
44
-6
7.74M
$15.5M
Q4 2025
78
+34
51.78M
$249.9M
Q1 2026
103
+25
85.32M
$593.0M
Q2 2026
126
+23
100.23M
$693.7M
Q3 2026
77
-49
46.45M
$176.0M
Each point is a quarter-end, from Q4 2019 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (75955J402). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2019) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.